Overview of Zocardis 30

Property	Description
Active ingredient	Zofenopril calcium
Form	Film-coated tablet (Oral)
Pharmacological class	ACE Inhibitor
Common use	Cardiovascular flow management
Origin	Synthetic compound

What Type of Medicine is Zocardis 30?

Zocardis 30 is a specific prescription-only medicine containing the active ingredient Zofenopril calcium. It is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, a major category of cardiovascular agents. Zocardis 30 is produced by A. Menarini, a key manufacturer in the international pharmaceutical supply chain, confirming its status as a regulated product.

As an ACE inhibitor, the compound is a synthetic chemical entity that functions by intervening in the body's natural system for regulating blood pressure. Zofenopril is pharmacologically a highly lipophilic (fat-soluble) prodrug, a characteristic that may contribute to its distinct bioavailability.

Composition and Form: What is Zofenopril?

Zocardis 30 is manufactured as a single-ingredient product, with Zofenopril calcium responsible for the primary therapeutic activity. The medicine is consistently presented as a film-coated tablet intended for oral consumption, which is the established route of administration for this type of long-term therapy.

The composition consists of the active substance, Zofenopril calcium, combined with necessary excipients required for forming the stable tablet structure. Zofenopril is chemically differentiated by the inclusion of a sulfhydryl group in its structure, a feature recognized for potentially offering additional protective qualities beyond standard ACE inhibition, particularly concerning the reduction of oxidative stress.

What is the General Purpose of Zocardis?

The general purpose of Zocardis is to act as a systemic agent that promotes vessel relaxation and helps manage fluid volume, thereby supporting the overall function of the heart and circulation. By inhibiting the ACE enzyme, the medicine systematically reduces resistance within the blood vessels, easing the workload required for the heart to circulate blood efficiently.

This fundamental physiological action establishes the drug's role as a primary tool for maintaining healthy blood pressure and managing conditions where reduced cardiac strain is crucial. Zofenopril is used to reduce high blood pressure and is particularly recognized for its application in patients following a heart attack.

What side effects are possible with Zocardis 30?

Possible side effects and safety information

This section describes the officially documented adverse reactions and safety characteristics of Zocardis 30 (Zofenopril calcium), as classified in regulatory documents like the Summary of Product Characteristics (SmPC) and FDA labeling. The information is organized by documented frequency and the body system affected.

Frequency-Classified Adverse Reactions

The most frequently reported adverse effects (classified as Common) include a persistent dry cough, dizziness, headache, fatigue, and low blood pressure (Hypotension). Less commonly documented effects (Uncommon) may involve sleep disturbances, taste changes (dysgeusia), diarrhea, or general weakness (asthenia). Severe adverse reactions are officially classified as Rare, such as Angioedema (swelling of the face, tongue, or throat) and severe blood disorders like Agranulocytosis.

Safety-Related Restrictions and Considerations

The regulatory profile outlines specific constraints on use. Zocardis 30 is Contraindicated in individuals with a history of Angioedema related to previous ACE inhibitor use, and its use is restricted with specific medications, such as Sacubitril/Valsartan, due to an increased safety risk. The medicine is also Contraindicated in the second and third trimesters of Pregnancy as it may cause harm to the fetus, and it is not recommended for use in children and adolescents. Special caution is required for patients with severe kidney or liver impairment, where it may be contraindicated or require dose adjustment. Low blood pressure is officially documented as being more likely to occur after the first dose of treatment.

Overdose and Emergency Response

Manifestations of Overdose

The official regulatory documents for Zocardis 30 define overdose based on exaggerated pharmacological effects, primarily profound hemodynamic instability. This may manifest as severe hypotension (excessively low blood pressure), tachycardia (increased heart rate), or bradycardia (slow heart rate). Acute renal failure is also a potential severe outcome documented in official labeling. Additionally, a critical risk involves life-threatening angioedema (swelling) of the face, lips, tongue, or throat. Patients who are volume- or electrolyte-depleted are noted to be at higher risk for developing severe acute hypotension following overexposure.

When to Seek Immediate Medical Help

Immediate medical attention must be sought if an overdose is suspected. Contact emergency services urgently if symptoms of circulatory shock, severe dizziness, fainting, or any sign of angioedema are present. Hospital monitoring and close medical supervision are explicitly required by regulatory authorities for all symptomatic patients and those at high risk.

Management and Monitoring

Management of overdose is strictly symptomatic and supportive. Regulatory statements confirm no specific antidote is known for Zofenopril overdose. Procedures officially described include placing the patient in a supine position and administering intravenous (IV) fluids for volume repletion. Monitoring should continue for an extended period, often 6 to 24 hours, and must include vital signs and laboratory findings.

Therapeutic Uses of Zocardis 30

Quick Facts

May assist in the management of elevated blood pressure (essential hypertension).
Can be used to help stabilize patients within the first day following an acute cardiac event.
Provides a treatment option to support cardiovascular health.

Zocardis 30 (containing zofenopril) is indicated for use in managing two primary cardiovascular conditions. The medication may assist in the long-term management of essential hypertension, which refers to sustained elevated blood pressure without an identifiable secondary cause. Treatment with this medication may contribute to the maintenance of appropriate blood pressure levels.

Additionally, Zocardis 30 is authorized for use in the treatment of patients initiated within the first 24 hours of an acute myocardial infarction (heart attack). In this context, the medication is intended to offer therapeutic support and may help stabilize the patient’s condition during this critical period.

The management of these specific conditions with this drug is part of a comprehensive strategy to support overall patient cardiovascular health.

Eligibility and Restrictions for Use

Zocardis 30 (zofenopril calcium), an ACE inhibitor, is subject to specific regulatory eligibility rules that define who can safely use the medicine. Eligibility is determined primarily by patient history, physiological status, and the presence of certain comorbidities.

Contraindications (Must Not Use)

Use of Zocardis 30 is absolutely contraindicated for the following populations, as stated in official labeling:

Patients with a history of angioedema (severe swelling) related to previous ACE inhibitor use, or those with hereditary or idiopathic angioedema.
Women in the second and third trimesters of pregnancy.
Patients with severe hepatic impairment (severe liver problems).
Patients with bilateral renal artery stenosis or stenosis of the artery to a solitary functioning kidney.
Individuals with hypersensitivity to zofenopril calcium or any other ACE inhibitor.

Use Not Established or Not Recommended

Population/Condition	Regulatory Status
Children and Adolescents (<18 years)	Not Recommended, as safety and efficacy have not been established.
Pregnancy (First Trimester)	Not Recommended. Must be avoided when planning pregnancy.
Lactation (Breastfeeding)	Not Recommended.
Renal Impairment (Moderate to Severe)	Special Caution/Restricted Use; requires dose adjustment and close monitoring. Not recommended in acute myocardial infarction patients with renal impairment.
Older Adults (ge 75 years)	Used with special caution in the context of acute myocardial infarction.

What should I know about interactions with other medicines?

Zocardis 30 Interactions with other medicines and products

Zocardis 30 (Zofenopril) interaction data is classified by regulatory bodies based on the mechanism and resulting constraint.

Contraindicated and Restricted Combinations

Co-administration with sacubitril/valsartan is formally contraindicated due to an increased risk of angioedema. Zofenopril must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan. The combination with aliskiren is also contraindicated for patients with diabetes mellitus or established renal impairment (GFR less than 60 ml/min/1.73 m^2). Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS) with Angiotensin II Receptor Blockers (ARBs) is generally not recommended.

Clinically Significant Pharmacodynamic Effects

Specific interactions are linked to additive pharmacodynamic effects:

Hyperkalemia: Concomitant use with potassium-sparing diuretics or potassium supplements may result in an increased risk of elevated serum potassium.
Angioedema: Co-administration with Racecadotril, mTOR inhibitors, or Vildagliptin is associated with a compounded risk of angioedema.
Renal Function: The combination with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect and increase the risk of renal function deterioration, particularly in the elderly.

Pharmacokinetic Notes

Use with Lithium is noted to increase serum lithium levels due to reduced renal clearance of lithium. Zofenopril can be administered before, during, or after meals, as a specific food interaction is not documented in the official regulatory information.

Mechanism of Action

Zocardis 30, containing the prodrug zofenopril, is rapidly hydrolyzed in the liver to its active metabolite, zofenoprilat.

Zofenoprilat functions as an inhibitor of the Angiotensin-Converting Enzyme (ACE), a zinc metalloprotease. The primary biological target is the tissue-bound and circulating ACE, particularly within the endothelium and vascular beds, where zofenoprilat exhibits high lipophilicity and tissue affinity.

Intracellularly, this inhibition blocks the enzymatic conversion of the inactive decapeptide Angiotensin I to the potent octapeptide Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS). The reduction in Angiotensin II concentration leads to a downstream cascade characterized by decreased stimulation of the AT1 receptors on vascular smooth muscle. Furthermore, ACE inhibition prevents the degradation of the potent vasodilator Bradykinin, leading to its accumulation.

The combined molecular consequences—reduced Angiotensin II-mediated vasoconstriction and increased Bradykinin-mediated vasodilation—result in systemic physiological modulation. This modulation manifests as decreased Total Peripheral Resistance and subsequently, reduced systemic vascular pressure. The sulfhydryl moiety of zofenoprilat may also confer interaction with reactive oxygen species, contributing to reduced oxidative processes within vascular tissue.

Dosage and Administration Information

Zocardis 30 is administered exclusively via the oral route as a film-coated tablet containing zofenopril calcium. The tablet can be taken independent of meals—either before, during, or after food—and may be broken in half to ease swallowing.

The usage pattern is dictated by the condition being managed. For the long-term management of essential hypertension, the standard starting dose is typically 15 mg once daily. The usual effective maintenance dose is 30 mg once daily, although the dose may be adjusted upwards, generally not exceeding 60 mg per day. Dose adjustments, if necessary, are typically made at intervals of four weeks.

For treatment initiated within 24 hours of an acute myocardial infarction (AMI), a different, rapidly escalating regimen is employed, which lasts for a course of six weeks. This regimen begins with a dose of 7.5 mg taken twice a day, increasing to 15 mg twice daily after two days, and reaching the maintenance level of 30 mg twice daily by the fifth day of treatment.

Specific dosage modifications are necessary for certain populations. Patients with moderate to severe kidney impairment (creatinine clearance ≤ 45 mL/min) or mild to moderate liver impairment are typically instructed to use half the standard therapeutic dose. For older adults, dosing remains unchanged unless reduced kidney function is also present. If a dose is missed, it should be skipped, and the patient should resume the scheduled dosing time without attempting to take a double dose.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Zocardis 30

This overview describes the types of clinical research that have been conducted on Zocardis 30 (Zofenopril calcium) and what the findings of these official studies suggest. This information reflects the known evidence base for the medicine.

Evidence Base for Early Treatment Following a Heart Attack

The core research evidence for Zofenopril in this context includes a large program of Randomized Controlled Trials (RCTs). Researchers initiated treatment with Zofenopril in stabilized adult patients who had recently experienced an acute myocardial infarction (heart attack), usually within the first 24 hours of symptom onset.

These studies monitored patients using pre-defined measures, typically tracking the rate of significant events, such as death or hospitalization for heart failure, over periods like 6 weeks and 1 year. The research examined these events in subgroups, including those who already had conditions like high blood pressure or diabetes. Data for long-term outcomes beyond the initial one-year follow-up are not fully established by the core randomized studies.

Evidence Base for the Management of Essential Hypertension

The use of Zofenopril for the long-term management of sustained essential hypertension (high blood pressure) has been the subject of multiple Randomized Controlled Trials and Meta-analyses. These studies explored Zofenopril both on its own (monotherapy) and in combination with a diuretic, against a placebo or against other anti-hypertensive drugs.

Research primarily focused on measuring systolic and diastolic blood pressure levels over defined time intervals. Studies reported the blood pressure levels observed across the observed time intervals. However, the dedicated Zofenopril trials in hypertension often involved medium-term follow-up (up to several months) for direct blood pressure outcomes.

Areas of Uncertainty and Research Gaps

Research on Zofenopril provides context about what has been observed so far. One key limitation is that comparative evidence remains limited for direct, long-term outcomes between Zofenopril and all other available ACE inhibitors. Furthermore, the data for certain groups remain insufficient, especially for those outside the main study criteria, such as pediatric patients. The study results reflect the specific conditions and cohorts under which they were conducted, and research does not determine whether an individual will respond similarly.

Key Studies & References

National Institute for Health and Care Excellence (NICE): Hypertension in adults: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Zocardis 30 (FAQ)

Q: Does Zocardis 30 treat the cause of the condition or just the symptoms?

According to official product information, Zocardis 30 works by targeting a specific underlying physiological process: the body's system that regulates blood pressure. Its active substance, an ACE inhibitor, blocks an enzyme that constricts blood vessels. This action modulates the system itself, rather than only providing temporary symptom relief.

Q: If I stop taking Zocardis 30, what happens?

For chronic conditions like high blood pressure, stopping a medicine in this class may lead to a gradual return of blood pressure to pre-treatment levels. Regulatory documents do not describe a specific withdrawal syndrome. Any changes to the medication schedule are typically managed by a healthcare provider.

Q: Is it normal to feel a little dizzy when first starting Zocardis 30?

Dizziness is listed in official sources as a commonly reported side effect. Low blood pressure (hypotension), which can be associated with feeling dizzy, is specifically documented as being more likely to occur after the first dose of the treatment is taken.

Q: Is Zocardis 30 safe for people with kidney problems?

Official information indicates that Zocardis 30 requires special caution and close monitoring for people with existing kidney impairment. For patients with moderate to severe kidney function problems, a dose adjustment is typically required. The use of this medicine is restricted or contraindicated in certain severe kidney conditions.

Q: How quickly should I expect Zocardis 30 to start working?

The active substance in Zocardis 30 is rapidly converted to its active form in the body. While an initial physiological effect may begin relatively quickly, the blood pressure lowering observed in clinical use may take several weeks of consistent use to fully develop.

Q: Do the side effects of Zocardis 30 go away over time?

The persistent dry cough, which is a known side effect of this class of medicine, typically resolves after the treatment is stopped. The duration of other reported side effects, which vary in frequency and severity, is not uniformly defined in official regulatory documents.

Q: Where can I find the official prescribing information for Zocardis 30?

The official regulatory documents, which contain the comprehensive prescribing information for Zocardis 30 (Zofenopril calcium), are published by government and intergovernmental health authorities. These include resources like DailyMed from the U.S. National Library of Medicine, and information from the European Medicines Agency (EMA).

Q: What are the long-term effects of taking Zocardis 30?

Zocardis 30 is used for the long-term management of essential hypertension. Clinical trials for its use following a heart attack have monitored patients for cardiovascular outcomes over periods up to one year. Official documents list potential adverse effects based on the frequency with which they were reported in studies.

Q: Is Zocardis 30 a controlled substance?

No. Official regulatory documents, including those from the U.S. Drug Enforcement Administration (DEA) and other major bodies, do not classify Zocardis 30 (Zofenopril calcium) as a controlled substance.

Q: How long does Zocardis 30 stay in your system?

The active metabolite of Zocardis 30, zofenoprilat, is eliminated from the body via excretion pathways involving both the liver and the kidneys. The rate at which the active metabolite is removed is considered when establishing its dosing schedule.

Q: Is there a generic version of Zocardis 30 available?

The active ingredient in Zocardis 30 is Zofenopril calcium. The availability of a generic product containing Zofenopril calcium can vary significantly depending on the region and the specific drug market regulations in place.

Q: What color and shape is the Zocardis 30 tablet?

Zocardis 30 is manufactured and presented as a film-coated tablet. Specific regulatory documents detail the final pharmaceutical form of the product, which is intended for oral consumption.

Q: Does Zocardis 30 affect blood sugar levels?

Zocardis 30 is not a medicine for treating diabetes. However, official regulatory warnings note that combining Zocardis 30 with certain medicines used to treat diabetes may increase the documented risk of angioedema (severe swelling).

Q: Does Zocardis 30 have a risk of dependence or withdrawal?

Zocardis 30 belongs to a class of medicines that is not typically associated with dependence or a physical withdrawal syndrome. However, stopping the treatment for a chronic condition may result in the return of blood pressure to pre-treatment levels.

Q: What common over-the-counter cold medicines are restricted with Zocardis 30?

Official information specifically lists Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include certain common cold and pain relievers, as a known interaction. This combination may reduce the blood pressure lowering effect and increase the potential risk of kidney function problems.

Q: How often do people usually need checkups while taking Zocardis 30?

Blood pressure monitoring is routinely conducted as part of the overall treatment plan. Close monitoring of kidney function and electrolyte levels is specifically required for patients with existing kidney or liver impairment.

Q: Can Zocardis 30 affect my ability to drive or operate machinery?

Official product information states that due to the possibility of certain side effects, such as dizziness, especially when treatment is first initiated, the ability to drive or operate machinery may be affected.

Q: Are there any specific signs of an allergic reaction to Zocardis 30 I should know?

One severe adverse reaction documented in official sources is Angioedema, which involves swelling of the face, tongue, or throat. Hypersensitivity (allergic reaction) to zofenopril calcium or any other ACE inhibitor is listed as a contraindication for use.

Q: How long after stopping Zocardis 30 can I safely take interacting medicines?

Regulatory instructions specify that starting Zofenopril must not occur earlier than 36 hours after the last dose of sacubitril/valsartan, due to the risk of severe swelling. The specific time periods required for changing between Zocardis 30 and other interacting medicines are detailed in regulatory guidelines.

Q: Does Zocardis 30 require any special monitoring like blood tests?

Monitoring is required because the combination of Zocardis 30 with certain medicines, such as potassium-sparing diuretics, may increase the risk of elevated serum potassium. Additionally, the use of Zocardis 30 alongside Lithium may increase serum lithium levels, requiring regular checks.

Q: Can Zocardis 30 be cut in half or crushed?

Official instructions state that the film-coated tablet may be broken in half to ease swallowing, if necessary. Regulatory information does not explicitly provide guidance regarding crushing the tablet.

Q: Is Zocardis 30 a medication I will need to take long-term?

The required duration of use depends on the condition being addressed. Zocardis 30 is indicated for the long-term management of essential hypertension. For its use following an acute heart attack, the treatment is indicated for a course of six weeks.

How should Zocardis 30 be stored and disposed of?

How to Store and Dispose of Zocardis 30?

The official storage and disposal requirements for Zocardis 30 (zofenopril calcium) are defined by government regulatory documents, emphasizing environmental stability and safe handling.

Storage Requirements

Storage Condition	Official Requirement
Temperature and Environment	No special precautions for storage are required for the product in its original packaging.
Shelf Life	The official shelf life is typically 3 years.
Child Safety	The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Zocardis 30 and any associated waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Medicines should not be disposed of via household waste or wastewater to protect the environment. The product is not classified as requiring special handling as a hazardous medicinal product.

Zocardis 30